BioMADE’s Post

The U.S. has the feedstock advantage—now we need the biomanufacturing infrastructure to match. At Synonym, we believe the future of biomanufacturing hinges not just on scientific breakthroughs, but on rethinking how we price, produce, and scale bio-based products. That’s why we’re focused on the same challenges Dr. Doug Friedman highlights in this podcast episode: infrastructure and business model innovation. In a must-listen episode of Lexicon, Dr. Douglas Friedman, CEO of BioMADE, breaks down what it will take for the U.S. to lead the global biomanufacturing race—and why time is of the essence. Key takeaways: 1/ The U.S. has a global advantage in agricultural feedstocks, but we’re lagging in manufacturing infrastructure. 2/ Biomanufacturing is about more than sustainability—it’s about national security and industrial competitiveness. 3/ BioMADE is spearheading a $1.5B effort to close the infrastructure gap with new pilot-scale facilities. 4/ The biggest innovations ahead might not be in science—but in business models and supply chains. We’re proud to be a member of BioMADE and fully aligned with their mission to turn biology into economic and environmental impact. At Synonym, our work is rooted in helping companies understand the economics of biomanufacturing—and in building the infrastructure needed to close the scale-up gap. If you care about the future of the bioeconomy, this conversation is worth your time. Listen to the full episode here: https://lnkd.in/eJwnKiz2 #biotechnology #biomanufacturing #innovation #bioeconomy #fermentation